Skip to main content
보도자료 배포 뉴스와이어
검색폼
검색
로그인
회원가입
보도자료
서비스
교육
블로그
보도자료 배포
보도자료 구독
고객센터
보도자료 배포 서비스
보도자료 배포 뉴스와이어
보도자료 배포
보도자료 구독
고객센터
로그인
회원가입
보도자료
서비스
교육
블로그
통합검색
보도자료
사진
동영상
기업
박람회
FAQ
취소
기업 검색
보도자료 등록
최신
IT
건강
경제
교육
금융
농수산
라이프
레저
문화
미디어
부동산
사회
산업
스포츠
에너지
운송
유통
자동차
정책
신상품
상장기업
주요
최신 보도자료
MY뉴스
상장기업
사진
동영상
기업뉴스룸
박람회
인기 토픽
보도자료 분야와 RSS
English News
산업별
IT
건강
경제
교육
금융
농수산
라이프 스타일
레저
문화/연예
미디어
산업별
부동산
사회
산업
스포츠
에너지/환경
운송
유통
자동차
정책/정부
주제별
개발
공모/모집
기업문화
부고
분양
사업계획
사회공헌
선언/의견
설립/오픈
소송
수상/선정
수주
주제별
신상품
실적
인물동정
인사
인수/합병
전시/출품
정책
제휴
조사연구
채용
투자
판촉활동
지역별
서울
인천/경기
대전/충남
광주/전남
부산/울산/경남
대구/경북
강원
충북
전북
제주
해외
기업 뉴스룸
Boehringer Ingelheim International GmbH
이 회사 보도자료 구독
제약
INGELHEIM, Germany
http://www.boehringer-ingelheim.com
Boehringer Ingelheim International GmbH 보도자료
337개
RSS
이메일
2016년 11월 29일
09:45
Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss
Boehringer Ingelheim and China Southeast University Institute of Life Sciences today announced the start of a joint research project to develop new treatment approaches for hearing loss through regeneration of hair cells from inner ear stem cells. Th
건강
제약
제휴
2016년 11월 17일
09:55
Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD
Boehringer Ingelheim welcomes the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy which now positions a combination of a LAMA (long-acting anticholinergic) and a LABA (long-acting beta2-agonist), as a mainstay trea
건강
제약
개발
2016년 11월 17일
09:50
Updated Phase III Results Reinforce Safety and Efficacy of Praxbind® (idarucizumab) in Urgent Situations
Boehringer Ingelheim announced updated results from data for 494 patients participating in the ongoing phase III RE-VERSE AD™ study, which showed that administration of 5g of idarucizumab immediately reversed the anticoagulant effect of dabigatran, t
건강
제약
개발
2016년 11월 15일
13:55
Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
New data presented at the American Heart Association Scientific Sessions 2016 showed that Jardiance® (empagliflozin) consistently reduced the risk for cardiovascular death, regardless of the type of cardiovascular disease at baseline, compared with p
건강
제약
개발
2016년 11월 14일
11:30
Patient enrolment completed for RE-DUAL PCI™ study assessing dabigatran in atrial fibrillation patients after PCI with stenting
Patient enrolment into the international Phase IIIb RE-DUAL PCI™ study is complete.[1] The study evaluates the safety and efficacy of dabigatran etexilate (marketed as Pradaxa®) in atrial fibrillation (AF) patients undergoing a percutaneous coronary
건강
제약
개발
2016년 11월 8일
18:15
New European study highlights differing priorities in physician’s therapy goals when treating advanced lung cancer patients
Results from a survey analysing the prescribing behaviour of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been published in Clinical Lung Cancer. The research examined the primary therapy goal of phy
건강
제약
조사연구
2016년 11월 2일
11:05
Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016
Boehringer Ingelheim today announced results from the LUX-Lung 7 trial that directly compared the efficacy and safety of second-generation EGFR-directed therapy afatinib* (Giotrif®) and first-generation gefitinib (Iressa®), in the first-line treatmen
건강
제약
개발
2016년 10월 27일
11:15
Boehringer Ingelheim’s adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study
Boehringer Ingelheim today announced top-line results from the pivotal Phase III clinical study of BI 695501, a biosimilar candidate to U.S.-licensed Humira® and EU approved Humira® (adalimumab). BI 695501 met the clinical study primary efficacy endp
건강
제약
개발
2016년 9월 30일
09:45
Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies
Boehringer Ingelheim and Sarah Cannon Research Institute, the research arm of Sarah Cannon, the global cancer institute of HCA, announced today a new strategic collaboration. This partnership brings together Boehringer Ingelheim’s extensive experienc
건강
제약
제휴
2016년 9월 29일
11:50
Boehringer Ingelheim Boosts Immune-Oncology Pipeline Through Collaboration with ViraTherapeutics
Boehringer Ingelheim and ViraTherapeutics today announced a long term collaboration to jointly develop a next generation oncolytic virus therapy platform and to investigate ViraTherapeutic’s lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) gly
건강
제약
개발
2016년 9월 21일
13:50
New survey reveals 9 out of 10 patients with IPF were happy with how their doctor told them about their IPF diagnosis
A diagnosis of IPF is news that few patients want to hear from their physician, but the reality is that approximately 3 million people worldwide are living with idiopathic pulmonary fibrosis (IPF). It’s a rare and devastating disease with a median li
건강
제약
조사연구
2016년 9월 19일
10:15
Glyxambi® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European Union
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of Glyxambi® (empagliflozin/linagliptin) for use in adults with type 2 diabetes (T2D). Glyxambi®, from the Boehringer Inge
건강
제약
개발
2016년 9월 12일
13:50
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Boehringer Ingelheim today announced that the European Commission (EC) and U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including
건강
제약
수상/선정
2016년 9월 8일
15:50
New analysis showed dose adjustment of Giotrif® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer
Results from a new post-hoc analysis of two large Phase III trials (LUX-Lung 3 and LUX-Lung 6) assessing the impact of dose adjustments for Giotrif® (afatinib*) in patients with advanced non-small cell lung cancer (NSCLC) were published in Annals of
건강
제약
개발
2016년 9월 8일
11:00
New long-term data demonstrates continued safety and beneficial effect of OFEV® (nintedanib) for patients with IPF
Boehringer Ingelheim presented eight IPF-related abstracts at the European Respiratory Society (ERS) International Congress 2016, including new interim data from the INPULSIS®-ON extension trial assessing long-term treatment with OFEV® (nintedanib).
건강
제약
개발
2016년 9월 7일
11:30
Tiotropium Respimat® improved lung function in children with asthma aged 6-17 and is well-tolerated compared to placebo in children aged 1-17[1-5]
Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma® trial that showed adding tiotropium Respimat® to maintenance asthma therapy significantly improved lung function, as measured by FEV1(0-3h), in children aged 6
건강
제약
개발
2016년 9월 6일
10:15
New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD
Boehringer Ingelheim today announced the first results from the Phase III PHYSACTO® trial that shows Spiolto® (tiotropium+olodaterol) Respimat®, combined with exercise training, helps people with COPD walk for longer periods of time compared to those
건강
제약
개발
2016년 9월 6일
09:55
Simple blood test combined with exacerbation history may help to identify when to add ICS to COPD treatment
Boehringer Ingelheim today announced a new post-hoc subanalysis of the WISDOM study that suggests only 4 out of 100 people with chronic obstructive pulmonary disease (COPD), who have a history of frequent exacerbations and raised eosinophil levels (≥
건강
제약
개발
2016년 8월 30일
19:15
ESC Congress 2016 Late Breaking Science Registry
First outcome results from the GLORIA™-AF Registry show that treatment with dabigatran etexilate was associated with low incidences of stroke, major bleeding and life-threatening bleeding. The results from approximately 3,000 patients with non-valvul
건강
제약
개발
2016년 8월 16일
13:35
Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice
Boehringer Ingelheim today announces its global RE-VECTO program for Praxbind® (idarucizumab), the specific reversal agent for Pradaxa® (dabigatran etexilate).[1,2] Praxbind® is approved to reverse the anticoagulant effects of Pradaxa® in rare critic
건강
제약
개발
2016년 7월 20일
17:35
The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. It is also a great challenge for the medical personnel treating the patient, trying to save their patients’ life and independence. If patients are trea
건강
제약
사업계획
2016년 7월 15일
10:25
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
Scotland--(BUSINESS WIRE)-- Boehringer Ingelheim and the University of Dundee will join forces in an exciting collaboration with the aim to develop a novel class of medicines that target disease causing proteins for degradation. The collaboration bri
건강
제약
제휴
2016년 7월 14일
13:40
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 836845, Boehringer Ingelheim’s insulin-like growth factor (IGF)-1/IGF-2 ligand neut
건강
제약
제휴
2016년 6월 30일
18:10
INMARK™ now enrolling: first study to evaluate the effect of OFEV® (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients
Boehringer Ingelheim today announces that the first patient has been enrolled in a new study, INMARK™, investigating the effect of OFEV® (nintedanib) on changes in specific blood biomarkers. These changes in biomarkers indicate the excessive scarring
건강
제약
개발
2016년 6월 15일
11:45
Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
New data showed Jardiance® (empagliflozin) reduced the risk for new-onset or worsening kidney disease by 39 percent versus placebo when added to standard of care in people with type 2 diabetes with established cardiovascular disease. Boehringer Ingel
건강
제약
개발
이전
5
6
7
8
9
다음
동영상
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine
회사 보도자료 구독
뉴스와이어 회원은 이 회사 보도자료를 이메일과
MY뉴스
를 통해 무료로 구독할 수 있습니다.
회원 가입하기